Loxo Oncology Obtains $24,000,000 Series B Funding Round

  • Feed Type
  • Date
    5/6/2014
  • Company Name
    Loxo Oncology
  • Mailing Address
    1 Landmark Square Stamford, CT 06901 USA
  • Company Description
    Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations.
  • Website
    http://www.loxooncology.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $24,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    With the proceeds from this financing, we are now in an even stronger position to advance our lead asset LOXO-101, currently in a Phase 1 dose escalation trial, and to expand our exciting discovery pipeline.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor

By posting a comment, you agree to our terms and conditions.